Letter abstract
Nature Medicine 14, 64 - 68 (2008)
Published online: 16 December 2007 | Corrected online: 9 January 2008 | doi:10.1038/nm1666
There is a Corrigendum (February 2008) associated with this Letter.
G12-G13–LARG–mediated signaling in vascular smooth muscle is required for salt-induced hypertension
Angela Wirth1, Zoltán Benyó1,2,7, Martina Lukasova1,7, Barbara Leutgeb1,6, Nina Wettschureck1, Stefan Gorbey3, Petra Örsy1, Béla Horváth1, Christiane Maser-Gluth1, Erich Greiner4,6, Björn Lemmer3, Günther Schütz4, J. Silvio Gutkind5 & Stefan Offermanns1
The tone of vascular smooth muscle cells is a primary determinant of the total peripheral vascular resistance and hence the arterial blood pressure. Most forms of hypertension ultimately result from an increased vascular tone that leads to an elevated total peripheral resistance1, 2, 3. Regulation of vascular resistance under normotensive and hypertensive conditions involves multiple mediators, many of which act through G protein–coupled receptors on vascular smooth muscle cells4. Receptors that mediate vasoconstriction couple with the G-proteins Gq-G11 and G12-G13 to stimulate phosphorylation of myosin light chain (MLC) via the Ca2+/MLC kinase– and Rho/Rho kinase–mediated signaling pathways, respectively4, 5, 6. Using genetically altered mouse models that allow for the acute abrogation of both signaling pathways by inducible Cre/loxP-mediated mutagenesis in smooth muscle cells, we show that Gq-G11–mediated signaling in smooth muscle cells is required for maintenance of basal blood pressure and for the development of salt-induced hypertension. In contrast, lack of G12-G13, as well as of their major effector, the leukemia-associated Rho guanine nucleotide exchange factor (LARG), did not alter normal blood pressure regulation but did block the development of salt-induced hypertension. This identifies the G12-G13–LARG–mediated signaling pathway as a new target for antihypertensive therapies that would be expected to leave normal blood pressure regulation unaffected.
- Institute of Pharmacology, University of Heidelberg, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany.
- Institute of Human Physiology and Clinical Experimental Research, Semmelweis University, Üllöi ut 78/A, 1082 Budapest, Hungary.
- Institute of Pharmacology, Medical Faculty Mannheim, University of Heidelberg, Maybachstrasse 14, 68169 Mannheim, Germany.
- Division of Molecular Biology of the Cell 1, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
- Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892-4340, USA.
- Present addresses: Solvay Arzneimittel GmbH, Hans-Böckler-Allee 20, 30173 Hannover, Germany (B.L.); EvotecOAI AG, Schnackenburgallee 114, 22525 Hamburg, Germany (E.G.).
- These authors contributed equally to this work.
Correspondence to: Stefan Offermanns1 e-mail: Stefan.Offermanns@pharma.uni-heidelberg.de
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Additive effects of statin and dipyridamole on cerebral blood flow and stroke protectionJournal of Cerebral Blood Flow & Metabolism Original Article
Arsenic Trioxide Induces Apoptosis of Cutaneous T Cell Lymphoma Cells: Evidence for a Partially Caspase-Independent Pathway and Potentiation by Ascorbic Acid (Vitamin C)Journal of Investigative Dermatology Original Article
Angiotensin II receptors and renin release in rat glomerular afferent arteriolesKidney International Original Article
See all 11 matches for Research
